^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HC-7366

    i
    Company:
    HiberCell
    Drug class:
    GCN2 activator
    Related drugs:
    Apply
    A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma (MK-6482-030) (NCT06234605)
    Phase 1
    HiberCell, Inc.
    Recruiting
    Last update posted :
    11/22/2024
    Initiation :
    04/29/2024
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    VHL
    |
    VHL mutation
    |
    Welireg (belzutifan) • HC-7366